Tag:
Sunesis Pharmaceuticals
Latest Headlines
Latest Headlines
Sunesis plots $15.5M offering to support trial
Sunesis Pharmaceuticals is offering 44.1 million units, each consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a public offering price of
ASH roundup: Ariad, Cephalon and Novartis make a splash
There's plenty of news spilling out of the ASH meeting today. Here's a roundup of the highlights.
Ariad Pharmaceuticals made a splash, says TheStreet, with promising early-stage data from AP24534,
SPOTLIGHT: Sunesis cuts 60 jobs
Sunesis Pharmaceuticals is realigning to focus on the development voreloxin (SNS-595), its lead drug candidate. The company is expanding activities around late-stage development of the drug and
ALSO NOTED: Cancer-sniffing dog being cloned; Investment spurs Bioton shares; Genetic Chemistry wins $23M contract; Tioga touts
> The world's top cancer-sniffing canine has been cloned, and her owners are planning a pack of clones to join the hunt for canine cancer detection. Researchers have been testing dogs' ability to
Sunesis pares staff in cost-cutting move
Sunesis Pharmaceuticals is paring 35 workers, or 25 percent of its staff, in an effort to pare out $10 million in costs. Research and general administrative areas will be cut the most as the
